Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Nasal Foralumab in Healthy Volunteers
NCT06879067Phase 1Completed
- Sponsor
- Tiziana Life Sciences
- Start
- Nov 2018
- Primary completion
- Jul 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of foralumab in multiple sclerosis (MS), Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS) (4 arms), sponsored by Tiziana Life Sciences. Primary endpoints: Adverse Events and Immune Effect. Started Nov 2018; status: completed.
02
Drugs
foralumab
03
Conditions
multiple sclerosis (MS)Alzheimer's disease (AD)amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT06879067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06879067.